SABCS

Why ‘A Simple Blood Draw’ Could Hold Valuable Breast Cancer Information

December 26th 2023, 8:00pm

Article

Dr. Heather Parsons of Dana-Farber Cancer Institute explains how a liquid biopsy could help patients with breast cancer and their care teams learn vital information.

Arimidex/Faslodex And Enhertu Has Metastatic Breast Cancer Antitumor Activity

December 17th 2023, 10:00pm

Article

Patients with chemotherapy-naïve, HER2-low hormone receptor-positive metastatic breast cancer experienced antitumor activity via combination therapy with Arimidex or Faslodex plus Enhertu, according to data from the phase 1b DESTINY-Breast08 trial.

Obesity May Lead to Aggressive Breast Cancer Tumor Biology

December 14th 2023, 2:00pm

Article

Data showed that metabolic and genetic factors could contribute to aggressive tumors in Latin American and non-Hispanic White patients with breast cancer.

Conference Highlights from SABCS

December 12th 2023, 12:00am

Podcast

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

Keytruda, Chemo Show Early-Stage Breast Cancer Event-Free Survival Benefits

December 10th 2023, 1:00am

Article

Presurgical Keytruda Plus Chemo, Postsurgical Keytruda Continued to Show Benefits in in patients with high-risk, early-stage triple-negative breast cancer.

Presurgical Opdivo, Chemo See High Response in Early-Stage Breast Cancer

December 9th 2023, 5:00pm

Article

Opdivo and non–anthracycline containing chemotherapy before surgery produced promising pathologic complete response rates regardless of whether Opdivo was administered before or during treatment with carboplatin and paclitaxel in patients with stage 1 to 2B triple-negative breast cancer.

Zanidatamab Plus Ibrance, Faslodex Show Promise in Advanced Breast Cancer

December 9th 2023, 3:00pm

Article

Preliminary study results examining the bispecific antibody, CDK4/6 inhibitor and hormone therapy combination in patients with advanced breast cancer were presented at SABCS.

Consider Endocrine Therapy Responses When Planning Chemo in Breast Cancer Subset

December 9th 2023, 1:39am

Article

Results from the ADAPTcycle trial found that endocrine therapy plus ovarian suppression can generate high response rates in patients with HR-positive, early breast cancer, regardless of age.

Tecentriq Plus Perjeta, Herceptin, Chemo Does Not Improve pCR in HER2+ Breast Cancer

December 8th 2023, 11:00pm

Article

A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete response in patients with HER2-positive operable breast cancer.

Kadcyla Is the ‘First Therapy to Show Improved Survival’ in a Breast Cancer Subset

December 8th 2023, 10:00pm

Article

Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing neoadjuvant therapy.